TrialInternational journal of clinical oncology2017

Dasatinib rapidly induces deep molecular response in chronic-phase chronic myeloid leukemia patients who achieved major molecular response with detectable levels of BCR-ABL1 transcripts by imatinib therapy.

Masayuki Shiseki et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.